{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-008357","form_type":"8-K","ticker":"APGE","cik":"0001974640","company_name":"Apogee Therapeutics, Inc.","filed_at":"2025-02-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.692553+00:00","generated_at":"2026-05-27T04:10:41.126297+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Apogee doses first patient in Part B of Phase 2 APEX trial for APG777 in atopic dermatitis","bullets":["Part A enrolled 123 patients (exceeded ~110 target) randomized 2:1 APG777 vs placebo; >90% power for primary endpoint.","Part A 16-week induction data expected mid-2025; maintenance data first half 2026; Part B 16-week data second half 2026.","APG777 modeled to exceed lebrikizumab exposures by ~30–40% with ~70–90% fewer maintenance injections vs current therapies.","Plans to initiate Phase 1b combo study of APG777 and APG990 (anti-OX40L) in AD in 2025 with readout in second half 2026.","Expansion plans include Phase 1b/2b asthma trials in 2025 and Phase 2 EoE trial in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-008357","json":"https://secwatch.observer/filing/0001104659-25-008357.json","markdown":"https://secwatch.observer/filing/0001104659-25-008357.md","text":"https://secwatch.observer/filing/0001104659-25-008357.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1974640/000110465925008357/0001104659-25-008357-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1974640/000110465925008357/tm255268d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T04:10:41.126297+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}